Can Symbicort (budesonide/formoterol) cause osteoporosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Symbicort Lead to Osteoporosis?

Yes, Symbicort (budesonide/formoterol) can contribute to decreased bone mineral density and potentially increase osteoporosis risk, particularly with long-term use, though the risk is lower than with systemic corticosteroids.

Understanding the Risk

The budesonide component of Symbicort is an inhaled corticosteroid (ICS) that, despite being designed for local lung delivery, does achieve systemic absorption and can affect bone metabolism 1. The FDA label explicitly warns that decreases in bone mineral density (BMD) have been observed with long-term administration of products containing inhaled corticosteroids 1.

Key Evidence from Clinical Studies

A 52-week study in COPD patients using Symbicort showed reassuring findings: mean changes in BMD were small (ranging from -0.01 to 0.01 g/cm²), and BMD remained stable over the entire treatment period for both total hip and spine regions 1. More recent research in 456 COPD patients confirmed that changes from baseline in lumbar spine BMD over 52 weeks were minimal (least squares mean range -0.12 to 0.38%) and not clinically meaningful 2.

However, a broader review found that inhaled corticosteroids cause a dose-related reduction in bone mineral density, with three cross-sectional studies demonstrating a dose-related increase in fractures compared to controls 3.

Risk Stratification and Monitoring

Patients at highest risk include those with:

  • Prolonged immobilization
  • Family history of osteoporosis
  • Postmenopausal status
  • Tobacco use
  • Advanced age
  • Poor nutrition
  • Chronic use of other bone-depleting drugs (anticonvulsants, oral corticosteroids)

1

Monitoring Recommendations

The FDA label strongly recommends:

  • Assess BMD prior to initiating Symbicort in high-risk patients
  • Monitor BMD periodically during treatment
  • If significant BMD reductions occur and Symbicort remains medically necessary, strongly consider medications to treat or prevent osteoporosis

1

Comparison with Other Corticosteroid Formulations

An important distinction: budesonide (whether inhaled or oral controlled-release) appears to have less impact on bone than systemic prednisolone. In Crohn's disease patients, those switching from prednisolone to budesonide showed improvement in bone density 4. Guidelines for inflammatory bowel disease specifically recommend that "the dose of glucocorticoids should be kept to a minimum and, where possible, non-systemic formulations or controlled release budesonide advised" 5.

Research in corticosteroid-naive Crohn's patients demonstrated that budesonide caused smaller reductions in BMD than prednisolone (mean -1.04% vs -3.84%; P = .0084) 4.

Clinical Management Strategy

For patients requiring Symbicort:

  1. Initial Assessment:

    • Evaluate all osteoporosis risk factors before starting therapy
    • Obtain baseline BMD in high-risk patients
    • Consider DEXA scan with vertebral fracture assessment
  2. Preventive Measures:

    • Ensure adequate calcium intake (1,000-1,200 mg/day)
    • Vitamin D supplementation (600-800 IU/day, targeting serum level ≥20 ng/ml)
    • Weight-bearing exercise
    • Smoking cessation
    • Limit alcohol to 1-2 drinks/day
  3. Pharmacologic Intervention:

    • For patients at moderate-to-high fracture risk on long-term Symbicort, consider bisphosphonates as first-line bone protection 6, 7, 8, 9
    • This is particularly important if patients have additional risk factors or previous fragility fractures
  4. Ongoing Monitoring:

    • Reassess BMD periodically (timing based on individual risk)
    • Monitor for height loss or new back pain (vertebral fractures)
    • Regular ophthalmologic exams (ICS can also increase cataract/glaucoma risk)

Important Caveats

The absolute risk of clinically significant bone loss or fracture in most Symbicort users is relatively low, especially compared to systemic corticosteroids. The 12-month COPD study showed that changes in posterior subcapsular cataract scores and BMD were similar across treatment groups, including the non-ICS formoterol-only group 1.

Do not discontinue necessary asthma or COPD therapy due to bone concerns alone—uncontrolled respiratory disease carries its own significant morbidity and mortality risks. Instead, implement bone-protective strategies while continuing effective respiratory management.

The risk appears dose-dependent, so using the lowest effective dose of Symbicort that controls symptoms is prudent 1, 3.

Related Questions

What is the maximum recommended dose of Symbicort (budesonide/formoterol) for adults and children?
What is the maximum recommended dose of Symbicort (budesonide/formoterol)?
Is it safe to prescribe Breztri (budesonide/formoterol/glycopyrrolate) together with a separate budesonide inhaler?
Does Zenhale (budesonide/formoterol) have the same level of evidence as Symbicort (budesonide/formoterol) for use in SMART (Single Maintenance And Reliever Therapy) or MART (Maintenance And Reliever Therapy) regimens?
What is the recommended asthma management protocol for an adult patient in Australia for a GP, including diagnosis confirmation, initial low‑dose inhaled corticosteroid (ICS) therapy, step‑up to a combination inhaler with long‑acting β2‑agonist (LABA), a personalized asthma action plan, and treatment of acute exacerbations?
What topical therapy is recommended for a patient with limited tinea corporis involving less than 5% of body surface?
In a 40-year-old male who ingested multiple digoxin tablets and has a history of heart failure with reduced ejection fraction of 5–10%, current methamphetamine use, nicotine dependence, and type 2 diabetes mellitus, what is the most appropriate inpatient cardiology plan of care?
Can the extended-release (XL) formulation of bupropion be split in half?
What is the recommended treatment plan for a malignant melanoma with a Breslow thickness of 0.9 mm?
How effective is Jascayd (nerandomilast) at the approved 18 mg twice‑daily dose for adults with idiopathic pulmonary fibrosis?
What laboratory tests should be ordered to evaluate infectious causes of unexplained weight loss?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.